Navigation Links
GSI to Present at Upcoming Investor Growth Conferences
Date:1/9/2008

BILLERICA, Mass., Jan. 9 /PRNewswire-FirstCall/ -- GSI Group Inc. (Nasdaq: GSIG), a leading manufacturer of laser-based precision motion products and systems, today announced it will be presenting at both the Needham & Company 10th Annual Growth Conference in New York City on January 10th and the Fifth Annual Sidoti & Company Emerging Growth Conference in Palm Beach Florida on January 22nd.

Mr. Robert Bowen, Chief Financial Officer, will be speaking at both events.

About GSI Group Inc.

GSI Group Inc. supplies laser-based precision motion products and systems to the global medical, semiconductor, electronics, and industrial markets. GSI Group Inc.'s common shares are listed on the NASDAQ exchange under the symbol GSIG.

Certain statements in this news release may constitute forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, Section 27A of the United States Securities Act of 1933 and Section 21E of the United States Securities Exchange Act of 1934. These forward-looking statements may relate to anticipated financial performance, management's plans and objectives for future operations, business prospects, outcome of regulatory proceedings, market conditions, tax issues and other matters. All statements contained in this news release that do not relate to matters of historical fact should be considered forward-looking statements, and are generally identified by words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "objective" and other similar expressions. Readers should not place undue reliance on the forward- looking statements contained in this news release. Such statements are based on management's beliefs and assumptions and on information currently available to management and are subject to risks, uncertainties and changes in condition, significance, value and effect. Other risks include the fact that the Company's sales have been and are expected to continue to be dependent upon customer capital equipment expenditures, which are, in turn, affected by business cycles in the markets served by those customers. Other factors include volatility in the semiconductor industry, the risk of order delays and cancellations, the risk of delays by customers in introducing their new products and market acceptance of products incorporating subsystems supplied by the Company, risks of currency fluctuations, risks to the Company of delays in its new products, our ability to continue to reduce costs and capital expenditures, our ability to focus R&D investment and integrate acquisitions, changes in applicable accounting standards, tax regulations or other external regulatory rules and standards, and other risks detailed in reports and documents filed by the Company with the United States Securities and Exchange Commission and with securities regulatory authorities in Canada. Such risks, uncertainties and changes in condition, significance, value and effect, many of which are beyond the Company's control, could cause the Company's actual results and other future events to differ materially from those anticipated. The Company does not, however, assume any obligation to update these forward- looking statements to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking statements. For more information contact: Investor Relations, 978-439-5511, Ray Ruddy, (ext. 6170)


'/>"/>
SOURCE GSI Group Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. STAAR Surgical to Present at the Tenth Annual Needham Growth Conference
2. Isolagen Inc. to Present at the 26th Annual JPMorgan Healthcare Conference
3. Emageon to Present at the 26th Annual JPMorgan Healthcare Conference
4. Warner Chilcott to Present at the 26th Annual JPMorgan Healthcare Conference
5. Covance to Present at 26th Annual JPMorgan Healthcare Conference
6. Cephalon to Present at the 26th Annual JP Morgan Healthcare Conference
7. Perrigo Company to Present at The 26th Annual JPMorgan Healthcare Conference
8. DaVita Inc. to Present at JPMorgan Healthcare Conference
9. Hologic to Present at the 26th Annual JP Morgan Healthcare Conference
10. WebMD to Present at Upcoming Investor Conferences
11. Neurochem to present at JPMorgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... Raton (PRWEB) , ... September 19, 2017 , ... ... the El Naturalista brand, developed by ACPG Laboratories, is coming soon to RonnieColemanNutrition.com. ... in Spain, and El Naturalista is a trusted, well-respected brand reliant on the ...
(Date:9/19/2017)... ... ... For decades doctors, nurses, and other healthcare providers have been trained to ... calculating their cardiovascular disease (CVD) risk in the next 10 years. , Imagine ... an estimated 10-year risk prediction! , Imagine if the weatherman says there is a ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... with the Davidson Fellows Scholarship on September 27 at a reception in Washington ... Technology, Engineering, Mathematics, Literature and Music. , “I am honored to be a ...
(Date:9/19/2017)... ... September 19, 2017 , ... Emergency nursing expertise, skill ... Emergency Nurse (CEN®) certification according to a large-scale study announced today by ... conducted by the Human Resources Research Organization (HumRRO) in late 2016 and early ...
(Date:9/18/2017)... Bangkok, Thailand (PRWEB) , ... September 19, 2017 ... ... in Asia Pacific’s protein ingredient market , expected to grow at the ... Frost & Sullivan sharing the ‘Global Food Protein Trends & Growth Opportunities in ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... Sept. 7, 2017   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade cell and tissue hypothermic storage ... Mike Rice , President and CEO, will be presenting ... Rodman & Renshaw 19 th Annual Global Investment ... (12:25 p.m. Pacific time). The conference is being held at ...
(Date:9/6/2017)... INDIANAPOLIS , Sept. 6, 2017 Eli ... today it will present new data for galcanezumab and ... Congress of the International Headache Society (IHC) taking place ... Lilly will highlight new, long-term data from ... two doses of galcanezumab (120 mg and 240 mg) ...
(Date:9/5/2017)... JERUSALEM , Sept. 5, 2017 Oramed Pharmaceuticals ... www.oramed.com ), a clinical-stage pharmaceutical company focused on the ... it has successfully concluded its meeting with the U.S. ... novel oral insulin formulation. ... that the regulatory pathway for submission of ORMD-0801, would ...
Breaking Medicine Technology: